MDR restricts bacterial dissemination out of the peritoneal cavity to the spleen. (A) CFUs per spleen from Tln1^fl/fl mice or Lyz2^Cre;Tln1^fl/fl mice at 16 h after i.v. E. coli infection. (B) CFUs per spleen from mice untreated or treated with heparin, anti-integrin β1 and β2 blocking antibodies, or hirudin at 16 h after i.v. E. coli infection. Differences between groups are not statistically significant. (C) CFU per spleen from F5 littermates and F5^−/−;AlbF5Tg mice at 16 h after i.v. E. coli infection. Differences are not statistically significant. Ctrl, control. (D) CFUs per spleen from untreated and heparin-treated mice at 16 h after i.p. E. coli infection. (E) CFUs per spleen from F5 littermates and F5^−/−;AlbF5Tg mice treated with anti-integrin β1 and β2 blocking antibodies at 16 h after i.p. E. coli infection. (F) CFUs per spleen from mice treated with anti-integrin β1 and β2 blocking antibodies and mice treated with hirudin and anti-integrin β1 and β2 blocking antibodies at 16 h after i.p. E. coli infection. (G) CFUs per spleen from Tln1^fl/fl mice or Lyz2^Cre;Tln1^fl/fl mice treated with hirudin at 16 h after i.p. E. coli infection. Differences are not statistically significant. Two-tailed t tests were used to test statistical significance for A and C–G. One-way ANOVA was used to test statistical significance for B. Symbols represent individual mice studied. Error bars represent ± SEM. All experiments were repeated at least one to three times. *, P < 0.05; **, P < 0.01; ***, P < 0.001.